Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

NCT03611569 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT03611569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03611569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease
Lead sponsor
H. Lundbeck A/S
Phase
Phase 1
Overall status
Completed
Start date
July 25, 2018
Completion date
July 26, 2021
Enrollment
74 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, parkinson disease